Aligning the digital and physical supply chain with Almac ONE™ delivers agility for global phase III study during COVID-19 pandemic

A complex operation at the best of times, COVID-19 presented additional barriers for sponsors committed to delivering the right drugs to the right patients at the right time and temperature.

A key learning from the pandemic has been the importance of clinical supply chain agility. Something that can only be realised when clear and complete visibility over each aspect of the supply chain is available to inform fast and effective decision making.

For one sponsor operating a global phase III open label study to assess the long-term safety of its trial drug designed to treat patients with a progressive respiratory disease, rapidly adapting its distribution strategy would be key to maintaining access to vital medication for its vulnerable patients.

Download our case study to learn how Almac ONE™ allowed for a rapid, cost effective, emergency response to allow for immediate supply chain continuity during COVID-19.